The healthcare industry has long been a contentious battleground where profit often takes precedence over patient care. A recent study published in The Journal of Health Economics sheds light on a concerning trend: cancer patients treated by physicians participating in the 340B Program are being prescribed more medications, including those outside clinical guidelines, without any improvement in survival rates.
The 340B Program, established by Congress in 1992 under Section 340B of the Public Health Service Act, was designed to support hospitals and clinics serving low-income communities by allowing them to purchase outpatient drugs at discounted rates. However, the program has undergone significant growth in recent years, with the number of eligible entities surpassing 60,000 and drug purchases under the program skyrocketing from $8 billion to $66 billion between 2013 and 2023.
Dr. Danea Horn of the University of California, San Francisco, conducted a study on the prescribing behavior of physicians treating breast cancer patients before and after participating in the 340B Program. The results were alarming, showing a significant increase in the likelihood of prescribing outpatient drugs per patient and a rise in the intensity of drug treatment, even with medications that did not align with clinical recommendations.
Despite the surge in medication use, there was no evidence of improved patient survival, echoing previous research that questioned the quality of care provided by hospitals participating in the 340B Program. The program has been criticized for distorting healthcare markets, inflating drug profit margins, and creating financial incentives for providers to overprescribe medications.
Recent studies have also revealed that 340B-eligible hospitals have profited substantially from outpatient drugs, leading to a reluctance to adopt cost-effective biosimilars in favor of expensive brand-name drugs with higher profit margins. Additionally, hospitals have strategically managed their patient mix to meet eligibility criteria and expand into wealthier neighborhoods to maximize profits from outpatient drug sales.
The 340B Program has inadvertently created a financial advantage for eligible entities, disadvantaging independent physician practices and for-profit hospitals that are ineligible for the program. This imbalance has driven vertical integration within the healthcare industry, with hospitals acquiring physician practices and expanding clinics to increase drug revenue, ultimately raising commercial prices and burdening patients financially.
While reforming the 340B Program presents political challenges due to entrenched financial and political interests, there is a growing awareness among the public about the program’s implications. Advocates for reform are calling for changes that prioritize patient empowerment and equitable healthcare practices over profit-driven motives.
In conclusion, the 340B Program has become a double-edged sword in the healthcare landscape, offering financial benefits to eligible entities while potentially compromising patient care. As the debate around healthcare reform continues to evolve, finding a balance between financial sustainability and patient well-being remains a critical challenge for the industry.
